Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jay Steven Loeffler, M.D.

Co-Author

This page shows the publications co-authored by Jay Loeffler and Rakesh Jain.
Connection Strength

1.636
  1. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006 Jan; 3(1):24-40.
    View in: PubMed
    Score: 0.340
  2. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol. 2015 Apr 01; 33(10):1197-213.
    View in: PubMed
    Score: 0.160
  3. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12.
    View in: PubMed
    Score: 0.153
  4. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
    View in: PubMed
    Score: 0.146
  5. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011 Jun; 8(6):344-56.
    View in: PubMed
    Score: 0.123
  6. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
    View in: PubMed
    Score: 0.115
  7. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009 Jun; 6(6):327-38.
    View in: PubMed
    Score: 0.108
  8. Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment. J Clin Oncol. 2008 May 20; 26(15_suppl):2009.
    View in: PubMed
    Score: 0.100
  9. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007 Aug; 8(8):610-22.
    View in: PubMed
    Score: 0.095
  10. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
    View in: PubMed
    Score: 0.091
  11. Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model. Radiat Oncol. 2021 Mar 04; 16(1):48.
    View in: PubMed
    Score: 0.061
  12. MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma. J Neurooncol. 2018 Jan; 136(1):63-71.
    View in: PubMed
    Score: 0.048
  13. Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13010.
    View in: PubMed
    Score: 0.027
  14. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol. 2009 Apr; 6(4):229-36.
    View in: PubMed
    Score: 0.027
  15. Do the dietary supplements epigallocatechin gallate or vitamin e cause a radiomodifying response on tumors in vivo? A pilot study with murine breast carcinoma. J Soc Integr Oncol. 2007; 5(1):11-7.
    View in: PubMed
    Score: 0.023
  16. Radiomodifying responses of vitamin E and epigallocatechin gallate supplementation during irradiation of implanted tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9601.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.